Category: Research

New Confirmatory “PRECISE-HD” study of Pridopidine in HD ready to start recruitment in June

Date of release: 07/07/2026 Dear HD Community, We would like to share an update on the confirmatory PRECISE-HD study (Pridopidine Phase 3 Study to Establish Clinical Impact and Safety in […]

Roche/Genentech Discontinuing Trials

Today Roche shared difficult news. After careful review of the data, they have decided to stop two of their Huntington’s disease studies: GENERATION HD2 and POINT-HD. We’ve provided an overview […]

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ Company intends to submit the BLA […]

Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington’s Disease

Twelve-month findings showed improvement in Composite Unified Huntington’s Disease Rating Scale (cUHDRS) scores from baseline of +0.38, compared to an expected decline of -0.92 points in propensity score-weighted natural history […]

Novartis shares encouraging news on a treatment for Huntington’s Disease

We have received an interesting update from the pharmaceutical company Novartis about the medicine they currently are testing for Huntington’s Disease.   Do you remember the study named PIVOT-HD done a […]

uniQure Provides Regulatory Update

Dear Huntington’s Disease Community, We are writing to share an update following our recent Type A meeting with the U.S. Food and Drug Administration (FDA.) On March 2, 2026, uniQure […]

Harness Therapeutics Nominates HRN001 Drug Candidate for HD and Launches Clinical Advisory Board

Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntington’s Disease and Establishes Clinical Advisory Board Cambridge, UK, 16 February 2026: Harness Therapeutics (‘Harness’), a biotechnology company unlocking previously undruggable […]

Novartis Announces INVEST-HD

Novartis development of Votoplam in HD: INVEST-HD Phase 3 trial information now available February 3rd 2026 Dear Huntington’s disease Community, We are delighted to share an update on the development […]

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Feb. 4, 2026– Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader […]

An Update on SKY-0515

Dear friends in the Huntington’s disease community, We’d like to share an update on ongoing research into SKY-0515, an investigational medicine being studied for Huntington’s disease (HD). A scientific press […]